Objective: Treatment of chronic total occlusion (CTO) with everolimus-eluting bioresorbable vascular scaffold (BVS) is safe and effective at short-term follow-up (FU). The current study investigated clinical and angiographic outcomes after treatment of CTO with BVS at >1 year.
stenosis and thrombosis.
Resorption of scaffold restores pulsatility, cyclical strain, physiological shear stress, and mechanotransduction. [1] Additional benefits include no restrictions on future percutaneous or coronary artery bypass grafting (CABG).
Further, when scaffolds are resorbed, normal bifurcation anatomy, flow, and vascular function will be restored, while jailed side branches (SBs) will be liberated.
A 5-year clinical and functional multi-slice computed tomography angiographic follow-up (FU) study after coronary implantation of Absorb BVS (Abbott Vascular, Inc., Santa Clara, CA, USA) in patients with de novo coronary artery disease reported low event rate and suggested sustained safety of the device. [2] However, information about angiographic FU data of Absorb BVS in CTO lesions is sparse.
Procedural feasibility of CTO treatment with BVS was demonstrated in our recent study, marked by acceptable clinical outcome at short-term FU. [3] Present study was investigation of clinical and angiographic outcomes at >1 year after treatment of CTO with Absorb BVS.
METHODS
A total of 30 consecutive patients who underwent successful recanalization of CTO with BVS between March 6, 2013 and March 29, 2015 in the Department of Cardiology of the Bezmialem Foundation University were included in the study. CTO was defined as thrombolysis in myocardial infarction (TIMI) grade 0 flow with estimated duration of occlusion of >3 months. Indications for revascularization included angina or equivalent, and/or evidence of myocardial ischemia. Patients were anticoagulated with unfractionated heparin using initial bolus of 70-100 U/kg and subsequent boluses targeted to activated clotting time of >300 seconds throughout the intervention. Patients were eligible if reference vessel diameter (RVD) was between 2.5 and 4.0 mm. There was no restriction with regard to lesion or occlusion length. Treatment strategy was to cover occluded segment and stenotic segment proximally and distally to occlusion with 1 or more BVSs. Postdilatation was mandatory to ensure optimal expansion and apposition. Dual antiplatelet therapy of acetylsalicylic acid 100 mg per day and clopidogrel 75 mg per day or ticagrelor 90 mg twice daily was prescribed for at least 12 months. Ticagrelor was mainly preferred in difficult or complicated cases, some of which resulted in target vessel revascularization (TVR) or target lesion revascularization (TLR). Clinical FU was conducted every 6 months.
Every patient provided written informed consent for procedure and subsequent anonymous FU data analysis for clinical research purposes. Ethics committee of the Bezmialem Foundation University approved the study.
Patient selection
Patients aged between 18 and 80 years, with 1 or more CTO, presenting with angina symptoms or equivalent, and/or reversible ischemia were included in the study.
Principal exclusion criteria included myocardial infarction (MI) in the territory of target CTO within 30 days or within 3 days in other territory, renal failure with serum creatinine level >3 mg/dL, other comorbid conditions with life expectancy <2 years, contraindication for aspirin or clopidogrel therapy, and women with childbearing potential. Cases with severe calcification or tortuous vessels were also excluded.
Angiographic success was defined as residual inscaffold diameter stenosis (DS) <30%, with TIMI flow grade 3 without occlusion of significant SBs, flow-limiting dissection, distal embolization, or angiographic evidence of thrombus. Procedural success was defined as composite endpoint of angiographic success without associated major, in-hospital, clinical complications (e.g., death, MI, stroke, emergency FU MI was diagnosed based on increase of cardiac troponins above 99 th percentile upper reference limit with at least 1 of the following observations: symptoms of ischemia; changes in electrocardiogram, i.e., new or presumed new significant ST-T changes, new left bundle branch block, or development of pathological Q-waves; imaging evidence of new loss of viable myocardium or new regional wall motion abnormality; or identification of intracoronary thrombus by angiography. Symptom-driven TLR consisted of repeat percutaneous coronary intervention (PCI) or CABG to treat luminal stenosis in scaffold or within 5 mm border proximal or distal to scaffold implanted at indexed procedure in presence of angina symptoms and/or MI.
Angiography and quantitative coronary angiography analysis
Coronary arteriography was performed according to standard procedures [4] using consecutive single-plane orthogonal projections of target lesion. Quantitative coronary angiography (QCA) was performed with the Cardiovascular Angiography Analysis System (CAAS) II (Pie Medical Imaging BV, Maastricht, The Netherlands). [5] Small radiopaque markers at the ends of the stent helped with localization of the radiolucent device for definition of in-scaffold segment. The following QCA parameters were computed before and after BVS implantation and at FU angiography: occlusion length, minimal lumen diameter (MLD) and area, and RVD.
Optical coherence tomography
Time-domain optical coherence tomography (OCT) examinations were performed using well-validated, non-occlusive technique. [6] Briefly, after wiring artery with guidewire as described, Dragonfly Duo imaging catheter (LightLab Imaging, Inc., Westford, MA, USA) was advanced distally to implanted stent and during continuous contrast media flush (Visipaque, iodixanol, GE Healthcare, Chicago, IL, USA), automatic pullback was performed.
OCT images were obtained along region of interest, which was the implanted stent plus 5 mm both proximal and distal. Off-line analysis was performed after careful recalibration of acquired images along reconstructed longitudinal segment. Mean proximal and distal RVD, in-scaffold MLD, minimal lumen area (MLA), DS and area stenosis (AS) were obtained along region of interest using automated algorithm.
Statistical analysis
Continuous variables were presented as mean (standard deviation) or median (interquartile range). Categorical variables were presented as number (percentage). Differences in proportions were tested with chi-square test, and differences in continuous variables were tested with Student's t-test. Statistical analysis was performed using SPSS software (SPPS Statistics 20; IBM Corp., Armonk, NY, USA).
RESULTS

Population and lesion characteristics
Baseline characteristics of the patients are provided in Tables 1 and 2. Thirty patients were treated with Absorb BVS for single CTO, while 5 patients underwent PCI for double CTO. Mean age was 57.8±9.6 years and 86.7% of the population was male. Three patients had suffered previous MI and 2 patients had undergone previous CABG. Nine patients had triple-vessel disease, while double-vessel disease was found in 14 patients, and 5 patients had single-vessel disease. Majority of lesions involved the right coronary artery (RCA) (40.0%), followed by the left anterior descending artery (LAD) (34.3%), and the left circumflex coronary artery (LCX) (25.7%). Most lesions were localized in proximal section of target vessel (51.4%), while 28.6% of cases consisted of mid-portion lesions, 14.3% ostial, and 5.7% distal lesions.
Occlusion length >20 mm was observed in majority of cases (57.1%), 11 cases had blunt stump, and 8 lesions were characterized by moderate to severe calcification. sion (range: 1-4 scaffolds) and diameter of 3.2±0.4 mm (range: 2.5-3.5 mm). Postdilation was performed in all patients with mean balloon diameter of 3.4±0.4 mm and inflated to a maximum pressure of 16.8±4.1 atm.
There were 5 SBs at occlusion site, consisting of 2 obtuse marginals (both first obtuse marginal) and 3 diagonal vessels (2 first diagonals, 1 second diagonal).
Provisional stenting was performed 3 times: Double-stent strategy was applied in 2 cases and double-BVS strategy was used with T-stenting technique in 1 case. One mini-crush procedure was performed with hybrid strategy using drug-eluting stent (DES) for the SB.
Quantitative coronary angiography
The results of QCA analysis are provided in Table  4 . Baseline analysis revealed mean lesion occlusion length of 40.07±17.52 mm with proximal RVD of 3.02±0.39 mm and distal RVD of 2.13±0.54 mm.
Directly after BVS deployment, in-scaffold MLD was measured at 2.51±0.51 mm, in-scaffold DS at 13.19±5.88% and in-scaffold AS was measured at 22.07±5.33%. At median FU time of 402
Procedural characteristics
Procedural characteristics of lesions can be seen in Table 3 . Antegrade approach was applied in 32 CTOs. Majority of these lesions were treated with single wire crossing. Parallel wire technique was conducted 5 times. In 3 cases treated via retrograde approach, reverse-CART technique was used.
In total, 75 Absorb BVS were implanted. All implantations were successful, with angiographic success rate of 97.1%. No MIs occurred after procedures.
Predilation was performed with balloon diameter of 2.5±0.8 mm and mean maximum inflation pressure of 13.8±2.7 atm.
Mean scaffold length was 58.3±23.3 mm (range: 18-102 mm) with mean of 2.3±0.9 scaffolds per le- 
Optical coherence tomography
Results of OCT analysis are presented in Table 5 . Six RCA cases, 3 LCX cases, and 1 LAD case were analyzed at FU with OCT. Two patients had double CTO. One patient with LCX lesion had TLR (79% AS), while another patient with RCA lesion had VR proximal to stented segment. Average in-scaffold MLD was measured at 2.56±0.47 mm. Excluding the case with TLR, AS ranged from 17.1% to 36.0%.
Clinical parameters and follow-up data
Clinical outcome parameters can be found in In this kind of lesion, delayed endothelialization with DES, especially if stent is suboptimally implanted, may be associated with higher and longerterm risk of stent thrombosis. In addition, "full metal jacket" may jail some significant SBs and may inhibit future surgical revascularization.
A recent study has shown that even for long lesions covered by BVS (109 visible SB analyzed in 35 CTO Marlborough, MA, USA) guiding catheter extensions might be a solution, as described in our previous publication. [3] Data about angiographic and clinical outcome analysis of BVS use in CTO cases are sparse; the CTO-ABSORB pilot study has reported good, noninvasive, angiographic and clinical outcome results of CTO PCI7. Multi-slice computed tomography performed at baseline and at 6 to 8 months revealed only 2 cases with in-scaffold stenosis, and no other adverse events were observed. Rate of MACEs was lower compared with the current study; however, clinical observation period and time until angiography were shorter, especially if we consider that in our study, with exception of 1 TLR and 1 TVR, remaining MACEs occurred after FU period of 6 months (Table  6 ). Thus, longer observation periods are of great importance to state efficacy and safety of Absorb BVS for CTO more precisely.
Majority of studies on BVS enrolled patients with relatively simple lesions, thus one-to-one comparison between BVS use in this lesion subset and CTOs might not be accurate: The ABSORB Cohort B trial, which recruited 101 patients with single or 2-vessel de novo disease, had only 1 case of TVR at 6 months FU. LLL was only 0.19±0.18 mm, with similar results at 2-year FU (0.27±0.20 mm). Although after 6 months there was significant reduction in MLA on intravascular ultrasound (IVUS), as compared with baseline (p<0.005), the scaffold area gradually increased with longer observation time. [9, 10] At 3-year FU, there were 7 cases (7%) of ischemia-driven TLR, MACE rate was 10.0%, and there were no instance of scaffold thrombosis.
cases), where incidence of SB occlusion might have been expected to be higher, only low rate of 6.4% was observed. [7] In the present study, all SBs on occlusion side, which were either treated provisionally or with double-stent strategy, including mini-crush and T-stenting techniques, were patent without significant restenosis.
Finally, absence of permanent metal endoluminal prosthesis should allow the vessel to regain its physiological properties. In this context, an OCT study conducted 5 years after elective first-in-man BVS implantation revealed favorable tissue response with late luminal enlargement and SB patency. [8] All struts had disappeared and been integrated within the neointima and underlying plaque, forming a homogeneous, signal-rich, low-attenuating layer. [8] One of the frequent concerns regarding use of BVS in complex lesion subset like CTOs is that due to thicker struts of Absorb BVS (currently 157 μm in comparison to around 70-85 μm with current-generation DES), limited distensibility with risk of scaffold fracture might be assumed to occur in comparison to DES. Regarding deliverability and deployment, in our study, all lesions were multiple predilated (2.7 balloons per CTO). Further, to overcome difficulties in steerability/trackability, we routinely exchanged CTO wire with extra-support guidewire (Grand Slam; Asahi Intecc Co. Ltd., Aichi, Japan) through a microcatheter after crossing the CTO lesion. To increase deliverability of BVS, particularly when angulation comes into play, use of anchoring balloon or application of GuideLiner (Vascular Solutions, Inc., Minneapolis, MN, USA) or Guidezilla (Boston Scientific Corp., Table 6 . Clinical events and MACEs in hospital and on follow-up. 
In hospital
Limitations of the study
This study had small sample size and was not randomized. Lack of OCT evaluation at index procedure was also a limitation.
Conflict-of-interest issues regarding the authorship or article: None declared LLL analyses of DES in CTOs have yielded similar results to those obtained in present study. Tian et al. reported 1-year LLL of 0.46±0.68 mm after DES implantation in angiography-guided cases, whereas in IVUSguided cases, LLL was markedly decreased (0.28±0.48 mm). [13] Thus, routine IVUS guidance might improve the results obtained in this study, as determination of scaffold size before implantation and malapposition post deployment might be stated precisely.
Conclusion
Current study has demonstrated acceptable angiographic and clinical mid-term results of Absorb BVS use in CTO lesions, comparable to DES. Furthermore, use of Absorb BVS might avoid risks associated with "full metal jackets" in long lesions, such as stent thrombosis, might allow for possible future coronary bypass surgery and restoration of vessel's physiological properties.
Clinical and imaging FU at future time points with more patients is required to fortify utility of current findings.
